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83% had not been fully immunised with heptavalent pneumococcal vaccine. A total of 112 were randomised to ABX and 111 to WW.
Study design
In design terms, the study was an investigator-blinded (but not parent-blinded), randomised controlled trial that was carried out in a single centre. Five of every 10 participants were assigned randomly to the immediate-ABX group and the other 5 to the WW group, to closely maintain the numbers of patients in the two groups within any given time period. The randomisation scheme was constructed using the random-number generator function in the SAS 8.2 software. The duration of follow-up was 12 days and 30 days. Ninety-four per cent of the participants were followed to the 30-day end point.
Analysis of effectiveness
The analysis of effectiveness was conducted on the basis of treatment completers only. The primary outcomes included parent satisfaction with AOM care, resolution of symptoms, AOM failure/recurrence, and nasopharyngeal carriage of Streptococcus (S.) pneumoniae strains resistant to ABX. The secondary outcomes included: medication-related adverse events; serious adverse events; unanticipated AOM-related office and emergency department visits and telephone calls; the child's absence from day care or school resulting from AOM; and the parent's absence from school or work because of their child's AOM.
The groups were shown to be comparable at the analysis.
Effectiveness results
Total parent satisfaction scores for the immediate-ABX group compared with the WW group were not different at day 12 (44.4 versus 44.0) or day 30 (44.6 versus 44.6). Compared with WW, symptom on days 1 to 10 resolved faster in children treated with immediate ABX. At day 12, 69% of tympanic membranes and 25% of tympanograms were normal among the immediate-ABX group, compared with 51% (tympanic membranes) and 10% (tympanograms) in the WW group. Parents of children in the ABX group gave their children fewer doses of pain medication than did parents of children in the WW group. Children in the ABX group experienced 16% fewer failures than children in the WW group. Of the children in the WW group, 66% completed the study without needing ABX.
Immediate ABX resulted in the eradication of S. pneumoniae carriage in the majority of children, but S pneumoniae strains cultured from children in the ABX group at day 12 were more likely to be multidrug-resistant than strains from children in the WW group ,(p<0.02). More ABX-related adverse events were noted in the ABX group than in the WW group (12% versus 5%). No serious AOM-related adverse events were observed in either group.
Clinical conclusions
Sixty-six per cent of children in the WW group completed the study without ABX. Parent satisfaction was the same between groups, regardless of treatment. Compared with WW, immediate ABX was associated with decreased numbers of treatment failures and improved symptom control. However, it increased ABX -related adverse events and there was a higher percentage carriage of multidrug-resistant S. pneumoniae strains in the nasopharynx at the day-12 visit.
Measure of benefits used in the economic analysis
No summary measure of benefits was derived. The study was therefore categorised as a cost-consequences analysis.
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Direct costs
The direct costs included the costs of medications only. The costs of ABX were calculated using Galveston community pharmacy retail charges (as of June 2004) and data on the numbers of initial prescriptions and failure or recurrence prescriptions for each intervention group. These calculations were simplified by assuming that all children were at the median age (1.6 years) and weight (11.5 kg) and were able to take oral ABX for all failure or recurrence episodes. Discounting was not necessary as the costs were incurred within a year. The price year was 2004.
Statistical analysis of costs
No statistical analysis of the costs was reported.
Indirect Costs
The indirect costs were not included because the number of visits and days of work lost by the parents were not significantly different between the groups.
Sensitivity analysis
No sensitivity analysis was reported.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
Children in the immediate-ABX group required 109 initial prescriptions for amoxicillin and 28 prescriptions of highdose amoxicillin-clavulanate for failure or recurrence episodes (total $5,167.26; $47.41 per child).
Children in the WW group required 34 prescriptions for amoxicillin and 4 prescriptions for high-dose amoxicillinclavulanate for failure or recurrence episodes (total $1,143.24; $11.43 per child).
Synthesis of costs and benefits
The costs and benefits were not combined.
Authors' conclusions
Sixty-six per cent of patients in the watchful waiting (WW) group completed the study without antibiotic treatment (ABX). Parent satisfaction was the same between groups, regardless of treatment. Compared with WW, immediate ABX was associated with a decreased number of treatment failures and improved symptom control. However, it increased ABX-related adverse events and there was a higher percentage carriage of multidrug-resistant Streptococcus (S.) pneumoniae strains in the nasopharynx at the day-12 visit.
CRD COMMENTARY -Selection of comparators
Although no explicit justification was given for the comparator used, immediate ABX would appear to represent current practice in the authors' setting. You should decide if it is a widely used health technology in your own area.
Validity of estimate of measure of effectiveness
The analysis was based on an investigator-blinded, randomised controlled trial, which was appropriate for the study question. The patient groups were shown to be comparable at analysis. However, as the authors acknowledged, since the study design was parent-unblinded, parent satisfaction might have been influenced by the parents' personal beliefs and preconceptions about the advantages or disadvantages of ABX.
